vTv Therapeutics to Participate in the 38th Annual ROTH Conference

Core Insights - vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes treatment [1][3] - The company will participate in the 38th Annual ROTH Conference, conducting a fireside chat and 1x1 investor meetings from March 22-24, 2026 [1][2] Company Overview - vTv Therapeutics specializes in oral, small molecule drug candidates aimed at treating diabetes and other chronic diseases, with cadisegliatin leading its clinical pipeline [3] - The company is investigating multiple molecules across various indications for chronic diseases [3] Product Details - Cadisegliatin (TTP399) is an oral small molecule, liver-selective glucokinase activator being studied in the US as a potential first-in-class treatment for type 1 diabetes [4] - In non-clinical studies, cadisegliatin has shown the ability to increase glucokinase activity independently from insulin, suggesting potential for improved glycemic control [4] - The product has received Breakthrough Therapy designation from the U.S. FDA, indicating its significance in treatment [4]